Comparative Pharmacology
Head-to-head clinical analysis: NOGENIC HC versus ORTHO CEPT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOGENIC HC versus ORTHO CEPT.
NOGENIC HC vs ORTHO-CEPT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NOGENIC HC contains hydrocortisone, a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription and reducing inflammation, immune responses, and cytokine production.
Combination oral contraceptive containing desogestrel and ethinyl estradiol. Inhibits ovulation by suppressing gonadotropin secretion; increases viscosity of cervical mucus, impeding sperm penetration; alters endometrial development.
NOGENIC HC is not a recognized drug. Please verify the name. No dosing information available.
One tablet (0.15 mg desogestrel / 0.03 mg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 placebo tablets (or 7 hormone-free days).
None Documented
None Documented
Terminal elimination half-life is 12-15 hours. In patients with hepatic impairment, half-life may be prolonged up to 24 hours; no dose adjustment required for renal impairment.
Desogestrel: 23 hours (terminal), Etonogestrel active metabolite: 30 hours (terminal); clinical steady state after 7-10 days
Primarily hepatic metabolism; biliary excretion accounts for approximately 80%; renal elimination of inactive metabolites less than 5% as unchanged drug.
Renal: 50% (metabolites), Biliary/fecal: 40% (metabolites and unchanged drug), 10% unchanged in urine
Category C
Category C
Hormonal Contraceptive
Hormonal Contraceptive